GSK & 3 leading institutions form EU consortium

A new European consortium has been formed including GSK and three leading research institutions, University of Oxford, Centre Hospitalier Universitaire Vaudois in Lausanne and the Bernhard-Nocht Institute, to help further advance development of a candidate vaccine against Ebola, which is being co-developed by GSK and the US National Institutes of Health (NIH).

The consortium is backed by funding of €15.1 million from the European Commission Directorate General for Research and Innovation as part of its dedicated Horizon 2020 programme supporting research into treatments and vaccines for Ebola. The consortium also expects to receive an additional €1.4 million from the Swiss government.

The funding is already helping to implement an ongoing trial of an Ebola candidate vaccine being carried out in 120 healthy adult volunteers in Lausanne, Switzerland. If the safety and immunogenicity data from this and other ongoing phase 1 trials are encouraging, the EC funding will enable the consortium to begin larger phase 2 trials in Africa, which could start as early as January 2015.

Cerus' Intercept Blood System for plasma receives US FDA approval

The US Food and Drug Administration (FDA) has approved Cerus Corporation's Intercept Blood System for plasma. The Intercept plasma system is approved for ex vivo preparation of plasma in order to reduce the risk of transfusion-transmitted infection (TTI) when treating patients requiring therapeutic plasma transfusion.

The Intercept Blood System inactivates a broad spectrum of enveloped viruses, non-enveloped viruses, Gram-positive and Gram-negative bacteria, spirochetes and parasites.

While current screening tests for a limited number of pathogens have lowered the risks from transfusion-transmitted infections, these tests are reactive approaches, requiring identification of specific pathogens for which tests can then be developed and implemented. In contrast, pathogen reduction by inactivation is a proactive safety measure-- the process can inactivate susceptible viruses, bacteria, and parasites present in plasma components independently of whether they have been identified as specific blood supply risks. This is critical because there is typically a lag between the emergence of new pathogens, and the recognition that an additional safety intervention may be needed.

"We believe this approval to be a pivotal step toward giving US blood centres a proactive approach for protecting the plasma supply," said William ‘Obi' Greenman, Cerus’ president and chief executive officer. "Cerus’ 22 year commitment to improving transfusion safety has been essential to achieving the US approval for Intercept plasma, and our continued work with FDA on reaching an approval decision for the Intercept Blood System for platelets."

PYRIDINES

PYRIDINES

1. 2-AMINO-5-BROMO PYRIDINE [CASNO: 1072-97-5]
2. 2-AMINO-3, 5-DIBROMO PYRIDINE [CASNO: 35486-42-1]
3. 2-AMINO-5-NITRO PYRIDINE [CASNO: 3073-77-6]
4. 2-HYDROXY-5-NITRO PYRIDINE [CASNO: 5418-51-9]
5. 4-NITRO-2-PICOLINE N-OXIDE [CASNO: 5470-66-6]
6. 4-CYANO-2-PICOLINE
7. 3-CYANO-2-CHLORO-4-PICOLINE
8. 4-NITRO-3-PICOLINE
9. 2-BROMO PYRIDINE [CASNO: 109-04-6]
10. 2-HYDROXY-5-AMINO PYRIDINE [
11. 3-NITRO-4-PICOLINE
12. 4-BROMO-2-PICOLINE [CASNO: 22282-99-1]
13. 2-HYDROXY PYRIDINE [CASNO: 142-08-5]
14. 2-METHOXY PYRIDINE [CASNO: 1628-89-3]
15. 3-AMINO PYRIDINE [CASNO: 462-08-8]
16. 4-AMINO PYRIDINE CASNO: 504-24-5]
17. 3-CYANO PYRIDINE [CASNO: 100-54-9]
18. 4-CYANO PYRIDINE [CASNO: 100-48-1]
19. 2-HYDROXY-3, 5-DIBROMO PYRIDINE [CASNO: 13472-81-6]
20. 5-AMINO-3-PICOLINE
21. 2-CHLORO-5-NITRO PYRIDINE [CASNO: 4548-45-2]
22. 2, 5-DI BROMO PYRIDINE [CASNO: 624-28-2]
23. 2-CHLORO-3-NITRO-4-PICOLINE
24. 2, 6-DICLORO-3-NITRO PYRIDINE [CASNO: 16013-85-7]
25. 2-AMINO-6-METHOXY-3-NITRO PYRIDINE [CASNO: 
26. 2-CHLORO-6-METHOXY-3-NITRO PYRIDINE [CASNO: 38533-61-8]
27. 2-CHLORO-6-AMINO PYRIDINE 
28. 2-BROMO-6-CYANO PYRIDINE
29. 6-CYANO-2-PICOLINE
30. 2.AMINO-5-BORMO-3-NITRO PYRIDINE [CASNO: 6945-68-2]
31. 2, 3-DI AMINO PYRIDINE [CASNO: 452-58-4]
32. 3-NITRO-2-PICOLINE
33. 2-METHOXY-5-AMINOPYRIDINE [CASNO: 6628-77-9]
34. 3-BROMO PYRIDINE [CASNO: 626-55-1]
35. 3-HYDROXY PYRIDINE [CASNO: 109-00-2]
36. 2-PICOLINE N-OXIDE [CASNO: 931-19-1]
37. 4-PICOLINE N-OXIDE [CASNO: 1003-67-4]
38. 3-PICOLINE N-OXIDE [CASNO: 1003-73-2]
39. 4-NITRO PYRIDINE N-OXIDE [CASNO: 1124-33-0]
40. PYRIDINE N-OXIDE [CASNO: 694-59-7]